Aphton Corporation and Pasteur Merieux Connaught Form Strategic Alliance.WOODLAND, Calif.--(BW HealthWire)--Feb. 18, 1997--Aphton Corporation (NASDAQ/NMS:APHT APHT Advance Physical Test ) is pleased to announce the signing of an agreement with Pasteur Merieux Connaught (Rhone-Poulenc Group), a leader in medical science and research and the world's largest vaccine manufacturer, for a strategic alliance for Aphton's immunotherapeutic product, Gastrimmune(TM), for all human cancer applications, including colorectal, stomach, liver and pancreatic cancers pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. . Under the terms of the twenty-year agreement, Aphton will be responsible for product development, clinical trials and regulatory agency regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. approvals, and Pasteur Merieux Connaught will be responsible for promotion, advertising, marketing, distribution and sales of Gastrimmune in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , Canada, Europe (including the C.I.S. countries) and Mexico. In addition, Aphton and Pasteur Merieux Connaught will enter into agreements providing for the supply of Gastrimmune to Pasteur Merieux Connaught and the supply of certain components of Gastrimmune and other Aphton products to Aphton. In consideration of the exclusive rights granted to Pasteur Merieux Connaught under the agreement, Pasteur Merieux Connaught will provide upfront consideration totaling $10 million to Aphton. In addition, Pasteur Merieux Connaught will fund the costs associated with product introduction, promotion, advertising and marketing throughout the territory covered by the agreement, which are expected to be substantial. Finally, under the auspices of the agreement Pasteur Merieux Connaught will provide Aphton with assistance in connection with the development and registration of Gastrimmune. Once sales of Gastrimmune commence, under the terms of the agreement Aphton will receive the majority of the profits from sales of Gastrimmune, with the balance of profits to be retained by Pasteur Merieux Connaught. Discussions are continuing between Pasteur Merieux Connaught and Aphton for marketing rights to Gastrimmune for Japan and other Asian markets. In addition, Aphton will also continue discussions with Pasteur Merieux Connaught and other drug companies to address the non- cancer, human applications of Gastrimmune (e.g., GERD GERD gastroesophageal reflux disease. GERD abbr. gastroesophageal reflux disease GERD and ulcers) and Aphton's product Gonadimmune(TM) for breast and prostate cancers. Aphton Corporation is a biopharmaceutical company developing products using its innovative vaccine-like technology for neutralizing hormones that participate in gastrointestinal cancers and other diseases, as well. These other diseases include: Gastroesophageal Reflux Disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. (GERD); ulcers (both peptic peptic /pep·tic/ (pep´tik) pertaining to pepsin or to digestion or to the action of gastric juices. pep·tic adj. 1. Relating to or assisting digestion. 2. and pain-killer induced); endometriosis endometriosis (ĕn'dəmē'trē-ō`sĭs), a condition in which small pieces of the endometrium (the lining of the uterus) migrate to other places in the pelvic area. ; and prostate, breast and endometrial cancers. In addition, Aphton has exclusive worldwide manufacturing, distribution and sales rights for an immunocontraceptive product, also utilizing vaccine-like technology. This product is in a clinical trial funded by the World Health Organization (WHO). Pasteur Merieux Connaught (Rhone-Poulenc Group) is the new trade name of Pasteur Merieux Serums and Vaccins SA (headquarters: Lyon, France) and all its subsidiaries worldwide, including Connaught Laboratories which operates in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . As the world leader in vaccines, Pasteur Merieux Connaught contributes to the protection and maintenance of human health by creating superior immunological products for the prevention and treatment of infectious diseases infectious diseases: see communicable diseases. and cancers. CONTACT: Aphton Corporation, Woodland J.L. Whitmore, 916/666-5226 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion